American Shared Hospital Services

American Shared Hospital Services(AMS)股票分析

$1.280

+0.020 (+1.59%)收盤時

Loading chart…
最高
1.280
開盤
1.270
成交量加權均價
1.26
成交量
27.80K
市值
20.46M
最低
1.210
成交金額
34.93K
企業價值/稅息折舊攤銷前利潤(TTM)
0.00

American Shared Hospital Services is a provider of turn-key technology solutions for stereotactic radiosurgery and advanced radiation therapy equipment and services. Its segments include Leasing and Retail. The Leasing segment comprises the Company’s medical equipment leasing. The Retail segment comprises facilities in Peru and Ecuador. Its Proton Beam Radiation Therapy Operations is an alternative to traditional external beam, photon-based radiation delivered by linear accelerators. Its Gamma Knife stereotactic radiosurgery, a non-invasive procedure, is an alternative to conventional brain surgery and/or radiation therapy. The Gamma Knife treats selected malignant and benign brain tumors, arteriovenous malformations, and functional disorders including trigeminal neuralgia (facial pain). It can be an adjunct to conventional brain surgery, radiation therapy, or chemotherapy. The Company provides radiation therapy services both domestically and internationally.

ashs.com

AI 分析 of American Shared Hospital Services (AMS)

買進

American Shared Hospital Services (AMS) is currently trading at $1.28, with a low RSI of 31.235 indicating it is oversold. The company reported a significant revenue growth of 19.2% year-over-year in Q2 2026, reaching $8.4 million, which shows strong operational performance. Additionally, the stock has a forward P/E ratio of 44.64, suggesting growth potential despite current losses. The main risk is the negative net income, which was -$998,000 in Q2 2026, but the improving cash flow and revenue growth provide a solid foundation for recovery.

估值指標

American Shared Hospital Services(AMS)目前預期本益比為 44.64,5 年平均預期本益比為 13.40。

預期本益比

高估
5 年均值 P/E
13.40
目前P/E
44.64
高估
38.95
低估
-12.15

預期 EV/EBITDA

嚴重低估
5 年均值 EV/EBITDA
0.00
目前EV/EBITDA
0.00
高估
0.00
低估
0.00

預期股價營收比

低估
5 年均值 P/S
0.48
目前P/S
0.00
高估
0.80
低估
0.16

Alphio AI 對 AMS 的價格情境

情境價格取自當年最後一個月度預測區間。機率為固定的模型權重(25 / 50 / 25),不構成保證。

樂

樂觀

樂觀 · 25%AMS

$3.00

情境價格

基

基準

基準 · 50%AMS

$2.96

情境價格

悲

悲觀

悲觀 · 25%AMS

$2.19

情境價格

事件時間軸

2025-12-01 (ET)

05:29:00

JPMorgan Downgrades ams OSRAM to Underweight, Price Target Cut to CHF 5.35

2025-11-13 (ET)

07:04:59

American Shared Hospital Announces Q3 EPS of 0c Compared to (3c) Last Year

2025-08-13 (ET)

07:07:11

American Shared Hospital reports Q2 EPS (4c) vs. 55c last year

2025-05-15 (ET)

07:02:10

American Shared Hospital reports Q1 EPS (10c) vs 2c last year

2025-04-04 (ET)

07:04:18

American Shared Hospital appoints Gary Delanois as CEO

資訊

AMS 常見問題 —— 由 Alphio AI 解答

American Shared Hospital Services is a provider of turn-key technology solutions for stereotactic radiosurgery and advanced radiation therapy equipment and services. Its segments include Leasing and Retail. The Leasing segment comprises the Company’s medical equipment leasing. The Retail segment comprises facilities in Peru and Ecuador. Its Proton Beam Radiation Therapy Operations is an alternative to traditional external beam, photon-based radiation delivered by linear accelerators. Its Gamma Knife stereotactic radiosurgery, a non-invasive procedure, is an alternative to conventional brain surgery and/or radiation therapy. The Gamma Knife treats selected malignant and benign brain tumors, arteriovenous malformations, and functional disorders including trigeminal neuralgia (facial pain). It can be an adjunct to conventional brain surgery, radiation therapy, or chemotherapy. The Company provides radiation therapy services both domestically and internationally. It operates in the Industrials sector (SERVICES-MEDICAL LABORATORIES industry).

American Shared Hospital Services (AMS) is currently trading at $1.28, with a low RSI of 31.235 indicating it is oversold. The company reported a significant revenue growth of 19.2% year-over-year in Q2 2026, reaching $8.4 million, which shows strong operational performance. Additionally, the stock has a forward P/E ratio of 44.64, suggesting growth potential despite current losses. The main risk is the negative net income, which was -$998,000 in Q2 2026, but the improving cash flow and revenue growth provide a solid foundation for recovery.

暫無貼文

註冊或登入後參與討論

本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。

開始交易